MCID: CHR070
MIFTS: 41

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 37 15
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 73
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 55

Classifications:



External Ids:

Disease Ontology 12 DOID:5213
ICD10 33 G61.81
ICD9CM 35 357.81
MeSH 44 D020277
NCIt 50 C84636
KEGG 37 H01527
UMLS 73 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to polyradiculoneuropathy and neuritis. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, t cells and skin, and related phenotype is homeostasis/metabolism.

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 polyradiculoneuropathy 30.7 ALB HLA-DRB1 IFNG IL17A MPZ NFASC
2 neuritis 30.5 IFNG MPZ PMP22
3 neuropathy, hereditary, with liability to pressure palsies 30.4 MPZ PMP22
4 chronic graft versus host disease 30.3 ALB IFNG
5 optic neuritis 30.3 HLA-DRB1 MPZ
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IFNG IL17A
7 guillain-barre syndrome 30.2 ALB MPZ PMP22
8 autoimmune disease 30.1 HLA-DRB1 IFNG IL17A
9 systemic lupus erythematosus 29.8 ALB HLA-DRB1 IFNB1 IFNG IL17A
10 multiple sclerosis 29.6 HLA-DRB1 IFNB1 IFNG IL17A MPZ PRF1
11 chronic inflammatory demyelinating polyneuropathy 12.3
12 lewis-sumner syndrome 11.7
13 chronic inflammatory demyelinating polyneuritis 11.5
14 x-linked charcot-marie-tooth disease 11.4
15 neuropathy 10.5
16 multifocal motor neuropathy 10.4
17 lupus erythematosus 10.4
18 diabetes mellitus 10.3
19 congenital hypomyelination neuropathy 10.2 MPZ PMP22
20 charcot-marie-tooth hereditary neuropathy 10.2 MPZ PMP22
21 foot drop 10.2 MPZ PMP22
22 roussy-levy hereditary areflexic dystasia 10.2 MPZ PMP22
23 charcot-marie-tooth disease, demyelinating, type 1f 10.2 MPZ PMP22
24 charcot-marie-tooth disease, axonal, type 2d 10.2 MPZ PMP22
25 charcot-marie-tooth disease, x-linked dominant, 1 10.2 MPZ PMP22
26 charcot-marie-tooth disease, demyelinating, type 1c 10.2 MPZ PMP22
27 neuropathy - hereditary 10.2 MPZ PMP22
28 charcot-marie-tooth disease, demyelinating, type 1b 10.2 MPZ PMP22
29 charcot-marie-tooth disease, axonal, type 2b 10.2 MPZ PMP22
30 motor peripheral neuropathy 10.2 MPZ PMP22
31 charcot-marie-tooth disease, demyelinating, type 1a 10.2 MPZ PMP22
32 myasthenia gravis 10.2
33 glomerulonephritis 10.2
34 ptosis 10.2
35 polyneuropathy 10.2
36 myasthenia gravis congenital 10.2
37 charcot-marie-tooth disease, demyelinating, type 1d 10.2 MPZ PMP22
38 berylliosis 10.2 HLA-DRB1 IFNG
39 chronic beryllium disease 10.2 HLA-DRB1 IFNG
40 eosinophilia-myalgia syndrome 10.2 HLA-DRB1 IFNG
41 pelizaeus-merzbacher disease 10.2 MPZ PMP22
42 acute disseminated encephalomyelitis 10.2 HLA-DRB1 MPZ
43 charcot-marie-tooth disease and deafness 10.2 MPZ PMP22
44 idiopathic bronchiectasis 10.2 HLA-DRB1 IFNG
45 histoplasmosis 10.2 HLA-DRB1 IFNG
46 peanut allergy 10.2 HLA-DRB1 IFNG
47 tuberculous peritonitis 10.2 ALB IFNG
48 fascioliasis 10.1 ALB IFNG
49 anteroseptal myocardial infarction 10.1 ALB HLA-DRB1
50 hypersplenism 10.1 ALB IFNG

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.23 ALB IFNB1 IFNG IL17A MPZ NFASC

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Not Applicable
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9 tannic acid Approved Phase 3
10
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
11
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
12 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
13 Fingolimod Hydrochloride Phase 3
14 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
15 Hormone Antagonists Phase 3,Phase 1,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
17 glucocorticoids Phase 3,Phase 1,Phase 2
18 Hormones Phase 3,Phase 1,Phase 2
19 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
20 Pharmaceutical Solutions Phase 3,Phase 2
21
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
22
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
23
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
24
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
25
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
26
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
27
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
28
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
29
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
32 Interferon-beta Phase 2
33 Antiviral Agents Phase 2
34 Anti-Infective Agents Phase 2
35 Adjuvants, Immunologic Phase 2,Phase 1
36 interferons Phase 2
37 Antioxidants Phase 2
38 Vitamin B9 Phase 2
39 Vitamins Phase 2
40 Protective Agents Phase 2,Phase 1
41 Thioctic Acid Phase 2
42 Trace Elements Phase 2
43 Alpha-lipoic Acid Phase 2
44 Folate Phase 2
45 Vitamin B Complex Phase 2
46 Micronutrients Phase 2
47 Antirheumatic Agents Phase 1, Phase 2,Phase 2
48 Gastrointestinal Agents Phase 1, Phase 2
49 Methylprednisolone acetate Phase 1, Phase 2
50 Krestin Phase 1, Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
6 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
7 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
8 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
9 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
11 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
12 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
13 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
16 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
17 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
18 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
19 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
20 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
21 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
22 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
23 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
25 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
26 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
27 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
28 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
29 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
30 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
31 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
32 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
33 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
34 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
35 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
36 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
37 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
38 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
39 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
40 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
41 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
42 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
43 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022 Not Applicable
44 Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Recruiting NCT03656640 Gammanorm
45 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
46 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
47 Transcriptome Analysis of the Peripheral Blood in CIDP Active, not recruiting NCT02404298 Not Applicable IVIg
48 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890 Not Applicable
49 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Not Applicable Standard of Care
50 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

41
Spinal Cord, T Cells, Skin, Brain, Tongue, Kidney, Bone

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 344)
# Title Authors Year
1
Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 30266626 )
2019
2
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. ( 29554579 )
2018
3
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
4
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
5
Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. ( 29709940 )
2018
6
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. ( 29603842 )
2018
7
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
8
Risk factors for osteoporosis in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29896772 )
2018
9
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
10
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29866282 )
2018
11
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
12
Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique. ( 29926221 )
2018
13
Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29999199 )
2018
14
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. ( 30001923 )
2018
15
Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. ( 30072201 )
2018
16
Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy: evaluation with simultaneous T2 mapping and neurography method with SHINKEI. ( 30160180 )
2018
17
Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. ( 30203907 )
2018
18
Chronic inflammatory demyelinating polyradiculoneuropathy: A case report. ( 30313036 )
2018
19
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
20
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
21
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
22
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
23
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
24
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
25
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
26
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
27
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
28
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
29
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
30
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
31
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
32
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
33
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
34
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
35
Clinical Characteristics and Treatment Response of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29911781 )
2017
36
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
37
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
38
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26977594 )
2016
39
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. ( 27241239 )
2016
40
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. ( 27286956 )
2016
41
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis. ( 28607734 )
2016
42
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. ( 27902997 )
2016
43
A Bodybuilder With Weak Hands and Feet: Corticosteroid-Responsive Pure Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy Following Anabolic Steroid Use. ( 27438336 )
2016
44
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27077919 )
2016
45
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data. ( 27313890 )
2016
46
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. ( 27380808 )
2016
47
Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27211560 )
2016
48
A case of a 17-year-old male with neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy presenting with tremor and ataxia. ( 27580761 )
2016
49
Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. ( 27838091 )
2016
50
A case of severe chronic inflammatory demyelinating polyradiculoneuropathy with monoclonal gammopathy of undetermined significance with alternating immunoglobulin class to IgM from IgA. ( 27580763 )
2016

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.8 ALB MPZ NFASC

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.54 IFNB1 IFNG PRF1
2 cell death GO:0008219 9.43 IL17A PMP22
3 peripheral nervous system development GO:0007422 9.4 NFASC PMP22
4 positive regulation of osteoclast differentiation GO:0045672 9.32 IFNG IL17A
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNB1 IFNG
6 positive regulation of interleukin-23 production GO:0032747 9.16 IFNG IL17A
7 positive regulation of killing of cells of other organism GO:0051712 8.96 IFNG PRF1
8 myelination GO:0042552 8.8 MPZ NFASC PMP22

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 IFNB1 IFNG IL17A

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....